Antiretroviral therapy of VIH infection:: duration and reasons for changing the first therapeutic regimen in 518 patients

被引:10
作者
Gratacòs, L
Tuset, M
Codina, C
Miró, JM
Mallolas, J
Miserachs, N
Martín-Conde, MT
del Cacho, E
de Lazzari, E
Ribas, J
Gatell, JM
机构
[1] Univ Barcelona, Hosp Clin, Fac Farm, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, Serv Enfermedades Infecciosas, Barcelona, Spain
[3] Univ Barcelona, IDIBAPS, Unidad Epidemiol & Bioestadist, Hosp Clin,Inst Invest Biomed August Pi Sunyer, Barcelona, Spain
来源
MEDICINA CLINICA | 2006年 / 126卷 / 07期
关键词
antiretroviral treatment; duration; adverse drug reactions; efficacy; withdrawal;
D O I
10.1157/13085280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: Different combinations of antiretroviral drugs are used as initial HIV therapy but comparative studies between them are not frequent. The objectives of this study are to determine the median duration of different therapy combinations in naive patients between 1998-2000 and the main reasons for changing or stopping this first antiretroviral therapy (ARVT). PATIENTS AND METHOD: This study included a total of 518 naive patients who began antiretroviral therapy patients from 1998-2000. Using a Kaplan-Meier analysis the median duration of different combinations was determined. In addition, the main reasons for changing or stopping this first treatment were analysed. RESULTS: First ARVT median duration was 427 days (IQR: 114-890). 47% of patients stopped their first therapy due to adverse effects, 6% voluntarily withdrew from it, in 9% of patients the therapy was not effective and 15% of them were lost of follow up. Only 9% of the continued with the same ARVT at the end of the study but if we add 7% of treatment simplifications we can consider 16% of first ARVT successful. CONCLUSIONS: A median duration of 427 days, similar to other studies, is shorter than we would prefer for HIV, a condition that requires continuous treatment. On the other hand, the study corroborates that secondary effects are the principal problem associated with ARVT.
引用
收藏
页码:241 / 245
页数:5
相关论文
共 18 条
[1]  
BHASKARAN K, 2003, 1 EACS RES PHARM WOR
[2]   Duration of highly active antiretroviral therapy regimens [J].
Chen, RY ;
Westfall, AO ;
Mugavero, MJ ;
Cloud, GA ;
Raper, JL ;
Chatham, AG ;
Acosta, EP ;
Taylor, KH ;
Carter, J ;
Saag, MS .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) :714-722
[3]  
Knobel H, 2000, Enferm Infecc Microbiol Clin, V18, P27
[4]  
López JRA, 2002, MED CLIN-BARCELONA, V119, P721
[5]   The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials [J].
Mannheimer, S ;
Friedland, G ;
Matts, J ;
Child, C ;
Chesney, M .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1115-1121
[6]   CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load [J].
Miller, V ;
Staszewski, S ;
Sabin, C ;
Carlebach, A ;
Rottmann, C ;
Weidmann, E ;
Rabenau, H ;
Hill, A ;
Lepri, AC ;
Phillips, AN .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :530-533
[7]  
Miro J M, 2000, Enferm Infecc Microbiol Clin, V18, P396
[8]   Changing patterns of mortality across Europe in patients infected with HIV-1 [J].
Mocroft, A ;
Vella, S ;
Benfield, TL ;
Chiesi, A ;
Miller, V ;
Gargalianos, P ;
Monforte, AD ;
Yust, I ;
Bruun, JN ;
Phillips, AN ;
Lundgren, JD .
LANCET, 1998, 352 (9142) :1725-1730
[9]   Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre [J].
Mocroft, A ;
Youle, M ;
Moore, A ;
Sabin, CA ;
Madge, S ;
Lepri, AC ;
Tyrer, M ;
Chaloner, C ;
Wilson, D ;
Loveday, C ;
Johnson, MA ;
Phillips, AN .
AIDS, 2001, 15 (02) :185-194
[10]   Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients [J].
Monforte, AD ;
Lepri, AC ;
Rezza, G ;
Pezzotti, P ;
Antinori, A ;
Phillips, AN ;
Angarano, G ;
Colangeli, V ;
De Luca, A ;
Ippolito, G ;
Caggese, L ;
Soscia, F ;
Filice, G ;
Gritti, F ;
Narciso, P ;
Tirelli, U ;
Moroni, M .
AIDS, 2000, 14 (05) :499-507